{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:27:10Z","timestamp":1794414430801,"version":"4.9.1"},"reference-count":273,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005972","name":"German Cancer Aid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.pharmthera.2026.109134","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:06:23Z","timestamp":1792623983000},"page":"109134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Nucleic acid therapeutics for reinvigorating p53 function in glioblastoma: concepts, limitations and recent advances"],"prefix":"10.1016","volume":"288","author":[{"given":"Alexander","family":"Hagstotz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Michen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilker Y.","family":"Ey\u00fcpoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Temme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.pharmthera.2026.109134_bb0005","first-page":"2300","article-title":"PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli","volume":"63","author":"Abe","year":"2003","journal-title":"Cancer Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109134_bb0010","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/sj.cgt.7700437","article-title":"Intra-arterial delivery of p53-containing adenoviral vector into experimental brain tumors","volume":"9","author":"Abe","year":"2002","journal-title":"Cancer Gene Therapy"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109134_bb0015","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/ni.1779","article-title":"RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate","volume":"10","author":"Ablasser","year":"2009","journal-title":"Nature Immunology"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109134_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16111389","article-title":"Design of experiments to tailor the potential of BSA-coated peptide nanocomplexes for temozolomide\/p53 gene co-delivery","volume":"16","author":"Afonso","year":"2024","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109134_bb0025","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.ymthe.2026.02.022","article-title":"Targeting glioblastoma with engineered oncolytic HSV","volume":"34","author":"Akl","year":"2026","journal-title":"Molecular Therapy"},{"issue":"7463","key":"10.1016\/j.pharmthera.2026.109134_bb0030","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109134_bb0035","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.tibtech.2020.04.008","article-title":"Minicircle DNA: The future for DNA-based vectors?","volume":"38","author":"Almeida","year":"2020","journal-title":"Trends in Biotechnology"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109134_bb0040","doi-asserted-by":"crossref","first-page":"R790","DOI":"10.1016\/j.cub.2020.05.051","article-title":"Scavenger receptors","volume":"30","author":"Alquraini","year":"2020","journal-title":"Current Biology"},{"key":"10.1016\/j.pharmthera.2026.109134_bb0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41416-025-03325-6","article-title":"Efficacy and safety of low- and high-intensity focused ultrasound in glioblastoma: A systematic review of preclinical and clinical studies","author":"Alrashidi","year":"2026","journal-title":"British Journal of Cancer"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109134_bb0050","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41593-020-00789-y","article-title":"Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization","volume":"24","author":"Antunes","year":"2021","journal-title":"Nature Neuroscience"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109134_bb0055","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02230-16","article-title":"Mechanism of enhanced HIV restriction by virion coencapsidated cytidine deaminases APOBEC3F and APOBEC3G","volume":"91","author":"Ara","year":"2017","journal-title":"Journal of Virology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109134_bb0060","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/01616412.1995.11740314","article-title":"Adenovirus-mediated P53 gene delivery inhibits 9l glioma growth in rats","volume":"17","author":"Badie","year":"1995","journal-title":"Neurological Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109134_bb0065","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/sj.cgt.7700009","article-title":"Combined radiation and p53 gene therapy of malignant glioma cells","volume":"6","author":"Badie","year":"1999","journal-title":"Cancer Gene Therapy"},{"key":"10.1016\/j.pharmthera.2026.109134_bb0070","doi-asserted-by":"crossref","first-page":"5990","DOI":"10.1038\/ncomms6990","article-title":"Numerical chromosomal instability mediates susceptibility to radiation treatment","volume":"6","author":"Bakhoum","year":"2015","journal-title":"Nature Communications"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1023\/A:1006476608036","article-title":"Adenoviral vector-mediated gene transfer: Timing of wild-type p53 gene expression in vivo and effect of tumor transduction on survival in a rat glioma brachytherapy model","volume":"49","author":"Bampoe","year":"2000","journal-title":"Journal of Neuro-Oncology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109134_bb0080","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.ccell.2026.03.003","article-title":"Cancer type-specific variation in patterns of driver alterations across 50,000 tumors","volume":"44","author":"Bandlamudi","year":"2026","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109134_bb0085","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/j.1460-2075.1993.tb05678.x","article-title":"mdm2 expression is induced by wild type p53 activity","volume":"12","author":"Barak","year":"1993","journal-title":"The EMBO Journal"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109134_bb0090","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.1007\/s11033-019-05093-y","article-title":"Evaluation of the CRISPR\/Cas9 directed mutant TP53 gene repairing effect in human prostate cancer cell line PC-3","volume":"46","author":"Batir","year":"2019","journal-title":"Molecular Biology Reports"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109134_bb0095","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/sj.cgt.7701076","article-title":"Targeted-simultaneous expression of Gas1 and p53 using a bicistronic adenoviral vector in gliomas","volume":"14","author":"Ben\u00edtez","year":"2007","journal-title":"Cancer Gene Therapy"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109134_bb0100","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s44321-024-00183-2","article-title":"CAR T-cell-associated secondary malignancies challenge current pharmacovigilance concepts","volume":"17","author":"Berg","year":"2025","journal-title":"EMBO Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2026.109134_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctro.2024.100833","article-title":"NANO-GBM trial of AGuIX nanoparticles with radiotherapy and temozolomide in the treatment of newly diagnosed glioblastoma: Phase 1b outcomes and MRI-based biodistribution","volume":"48","author":"Biau","year":"2024","journal-title":"Clinical and Translational Radiation Oncology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109134_bb0110","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/sj.gt.3300935","article-title":"Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule","volume":"6","author":"Biroccio","year":"1999","journal-title":"Gene Therapy"},{"issue":"3-4","key":"10.1016\/j.pharmthera.2026.109134_bb0115","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41434-020-00204-y","article-title":"Self-amplifying RNA vaccines for infectious diseases","volume":"28","author":"Bloom","year":"2021","journal-title":"Gene Therapy"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109134_bb0120","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/sj.onc.1209026","article-title":"Mutant p53 gain of function: Reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression","volume":"25","author":"Bossi","year":"2006","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109134_bb0125","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/jgm.611","article-title":"Suicide gene therapy with an adenovirus expressing the fusion gene CD::UPRT in human glioblastomas: Different sensitivities correlate with p53 status","volume":"6","author":"Bourbeau","year":"2004","journal-title":"Journal of Gene Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109134_bb0135","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1182\/blood-2001-11-0067","article-title":"Dangerous liaisons: The role of \"danger\" signals in the immune response to gene therapy","volume":"100","author":"Brown","year":"2002","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.pharmthera.2026.109134_bb0140","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb0145","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109134_bb0150","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/jgm.1205","article-title":"Recent developments in adeno-associated virus vector technology","volume":"10","author":"Buning","year":"2008","journal-title":"The Journal of Gene Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109134_bb0155","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/sj.mt.6300031","article-title":"Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors","volume":"15","author":"Cerullo","year":"2007","journal-title":"Molecular Therapy"},{"issue":"20","key":"10.1016\/j.pharmthera.2026.109134_bb0160","doi-asserted-by":"crossref","first-page":"R1010","DOI":"10.1016\/j.cub.2025.06.061","article-title":"The blood-brain barrier","volume":"35","author":"Chagnot","year":"2025","journal-title":"Current Biology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109134_bb0165","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11060-019-03230-y","article-title":"Absent in melanoma 2 regulates tumor cell proliferation in glioblastoma multiforme","volume":"144","author":"Chen","year":"2019","journal-title":"Journal of Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb0170","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41392-025-02264-1","article-title":"Pattern recognition receptors: Function, regulation and therapeutic potential","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109134_bb0175","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.nano.2015.10.021","article-title":"Transferrin-modified liposome promotes alpha-mangostin to penetrate the blood-brain barrier","volume":"12","author":"Chen","year":"2016","journal-title":"Nanomedicine"},{"issue":"7216","key":"10.1016\/j.pharmthera.2026.109134_bb0180","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","author":"Chin","year":"2008","journal-title":"Nature"},{"issue":"27","key":"10.1016\/j.pharmthera.2026.109134_bb0185","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2011.35.5222","article-title":"Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma","volume":"29","author":"Chiocca","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109134_bb0190","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/neuonc\/noab271","article-title":"Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial","volume":"24","author":"Chiocca","year":"2022","journal-title":"Neuro-Oncology"},{"issue":"505","key":"10.1016\/j.pharmthera.2026.109134_bb0195","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw5680","article-title":"Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial","volume":"11","author":"Chiocca","year":"2019","journal-title":"Science Translational Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109134_bb0200","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.cell.2009.06.015","article-title":"RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway","volume":"138","author":"Chiu","year":"2009","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb0205","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1073\/pnas.1219817110","article-title":"Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma","volume":"110","author":"Choi","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109134_bb0210","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-021-03657-0","article-title":"Mutation-specific non-canonical pathway of PTEN as a distinct therapeutic target for glioblastoma","volume":"12","author":"Choi","year":"2021","journal-title":"Cell Death & Disease"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109134_bb0215","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41434-025-00585-y","article-title":"Intranasal versus intravenous AAV delivery: A comparative analysis of brain-targeting efficiency and peripheral exposure in mice","volume":"33","author":"Chukwu","year":"2026","journal-title":"Gene Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000832","article-title":"U87MG decoded: The genomic sequence of a cytogenetically aberrant human cancer cell line","volume":"6","author":"Clark","year":"2010","journal-title":"PLoS Genetics"},{"issue":"34","key":"10.1016\/j.pharmthera.2026.109134_bb0225","doi-asserted-by":"crossref","first-page":"15051","DOI":"10.1073\/pnas.0910258107","article-title":"Dysregulation of the mevalonate pathway promotes transformation","volume":"107","author":"Clendening","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109134_bb0230","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/neuonc\/noz232","article-title":"A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)","volume":"22","author":"Cloughesy","year":"2020","journal-title":"Neuro-Oncology"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109134_bb0235","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1001\/jamaoncol.2020.3161","article-title":"Effect of vocimagene amiretrorepvec in combination with flucytosine vs standard of care on survival following tumor resection in patients with recurrent high-grade glioma a randomized clinical trial","volume":"6","author":"Cloughesy","year":"2020","journal-title":"JAMA Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109134_bb0240","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1021\/nn506248s","article-title":"Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles","volume":"9","author":"Cohen","year":"2015","journal-title":"ACS Nano"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109134_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102953","article-title":"The CINs of polo-like kinase 1 in cancer","volume":"12","author":"Cunningham","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.pharmthera.2026.109134_bb0250","doi-asserted-by":"crossref","unstructured":"delPeso, L., GonzalezGarcia, M., Page, C., Herrera, R., & Nunez, G. (1997). Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science, 278(5338), 687\u2013689. Retrieved from: \/\/WOS:A1997YC32300054.","DOI":"10.1126\/science.278.5338.687"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109134_bb0255","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1124\/jpet.107.131318","article-title":"Identification and design of peptides as a new drug delivery system for the brain","volume":"324","author":"Demeule","year":"2008","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109134_bb0260","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jmb.2013.10.033","article-title":"Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all","volume":"426","author":"Desimmie","year":"2014","journal-title":"Journal of Molecular Biology"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109134_bb0265","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/neuonc\/noac105","article-title":"EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: A noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma","volume":"24","author":"Ding","year":"2022","journal-title":"Neuro-Oncology"},{"issue":"16","key":"10.1016\/j.pharmthera.2026.109134_bb0270","doi-asserted-by":"crossref","first-page":"8367","DOI":"10.1128\/JVI.00423-12","article-title":"Vpu mediates depletion of interferon regulatory factor 3 during HIV infection by a lysosome-dependent mechanism","volume":"86","author":"Doehle","year":"2012","journal-title":"Journal of Virology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109134_bb0275","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3171\/jns.1998.88.3.0535","article-title":"Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function","volume":"88","author":"Dorigo","year":"1998","journal-title":"Journal of Neurosurgery"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109134_bb0280","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1111\/cas.14548","article-title":"Tetrahedral DNA nanostructures as drug delivery and bioimaging platforms in cancer therapy","volume":"111","author":"Duangrat","year":"2020","journal-title":"Cancer Science"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109134_bb0285","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1093\/neuonc\/noae177","article-title":"Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma","volume":"26","author":"Duerinck","year":"2024","journal-title":"Neuro-Oncology"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109134_bb0290","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1002\/ijc.27924","article-title":"Cancer cells preferentially lose small chromosomes","volume":"132","author":"Duijf","year":"2013","journal-title":"International Journal of Cancer"},{"issue":"6836","key":"10.1016\/j.pharmthera.2026.109134_bb0295","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/35078107","article-title":"Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells","volume":"411","author":"Elbashir","year":"2001","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109134_bb0300","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1021\/acsnano.8b08177","article-title":"Radiation-induced targeted nanoparticle-based gene delivery for brain tumor therapy","volume":"13","author":"Erel-Akbaba","year":"2019","journal-title":"ACS Nano"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109134_bb0305","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17091177","article-title":"Recent advances in nose-to-brain gene delivery for central nervous system disorders","volume":"17","author":"Fachel","year":"2025","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109134_bb0310","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41417-019-0113-y","article-title":"A simplified system for the effective expression and delivery of functional mature microRNAs in mammalian cells","volume":"27","author":"Fan","year":"2020","journal-title":"Cancer Gene Therapy"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109134_bb0315","first-page":"4522","article-title":"Overexpression of p53 delivered using recombinant NDV induces apoptosis in glioma cells by regulating the apoptotic signaling pathway","volume":"15","author":"Fan","year":"2018","journal-title":"Experimental and Therapeutic Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109134_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102671","article-title":"Nose-to-brain siRNA delivery by PEI\/PPI-based nanoparticles reduces \u03b1-synuclein expression in a Parkinson's disease mouse model","volume":"36","author":"Feja","year":"2025","journal-title":"Molecular Therapy--Nucleic Acids"},{"issue":"860","key":"10.1016\/j.pharmthera.2026.109134_bb0325","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adv8761","article-title":"Targeting therapeutic nanoparticles to the glioblastoma resection margin by harnessing postoperative blood-brain barrier disruption","volume":"18","author":"Fernandes","year":"2026","journal-title":"Science Translational Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109134_bb0330","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.sbi.2005.05.006","article-title":"Post-transcriptional gene silencing by siRNAs and miRNAs","volume":"15","author":"Filipowicz","year":"2005","journal-title":"Curr.Opin.Struct.Biol."},{"issue":"1-2","key":"10.1016\/j.pharmthera.2026.109134_bb0335","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.cell.2011.12.017","article-title":"Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway","volume":"148","author":"Freed-Pastor","year":"2012","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109134_bb0340","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1101\/gad.190678.112","article-title":"Mutant p53: One name, many proteins","volume":"26","author":"Freed-Pastor","year":"2012","journal-title":"Genes & Development"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb0345","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12885-016-3006-6","article-title":"Analysis of cellular and molecular antitumor effects upon inhibition of SATB1 in glioblastoma cells","volume":"17","author":"Fromberg","year":"2017","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb0350","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s12885-023-11043-6","article-title":"Use of bevacizumab in recurrent glioblastoma: A scoping review and evidence map","volume":"23","author":"Fu","year":"2023","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109134_bb0355","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0165-1110(92)90016-3","article-title":"Amplified cellular oncogenes in neoplasms of the human central nervous system","volume":"276","author":"Fuller","year":"1992","journal-title":"Mutation Research"},{"issue":"23","key":"10.1016\/j.pharmthera.2026.109134_bb0360","doi-asserted-by":"crossref","first-page":"12479","DOI":"10.1073\/pnas.94.23.12479","article-title":"Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain","volume":"94","author":"Furnari","year":"1997","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2026.109134_bb0365","doi-asserted-by":"crossref","unstructured":"Gah\u00e9ry-S\u00e9gard, H., Farace, F., Godfrin, D., Gaston, J., Lengagne, R., Tursz, T., \u2026 Guillet, J. G. (1998). Immune response to recombinant capsid proteins of adenovirus in humans: Antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. Journal of Virology, 72(3), 2388\u20132397. Retrieved from:\/\/WOS:000071997600081.","DOI":"10.1128\/JVI.72.3.2388-2397.1998"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109134_bb0370","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3390\/pharmaceutics6040557","article-title":"Smuggling drugs into the brain: An overview of ligands targeting Transcytosis for drug delivery across the blood-brain barrier","volume":"6","author":"Georgieva","year":"2014","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb0375","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13058-020-01370-y","article-title":"Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells","volume":"22","author":"Ghaleb","year":"2020","journal-title":"Breast Cancer Research"},{"issue":"6005","key":"10.1016\/j.pharmthera.2026.109134_bb0380","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1194637","article-title":"Fate mapping analysis reveals that adult microglia derive from primitive macrophages","volume":"330","author":"Ginhoux","year":"2010","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109134_bb0385","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/stem.1350","article-title":"Targeting the cytosolic innate immune receptors RIG-I and MDA5 effectively counteracts cancer cell heterogeneity in glioblastoma","volume":"31","author":"Glas","year":"2013","journal-title":"Stem Cells"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109134_bb0390","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1158\/2159-8290.CD-15-1154","article-title":"Chromosomal instability affects the tumorigenicity of glioblastoma tumor-initiating cells","volume":"6","author":"Godek","year":"2016","journal-title":"Cancer Discovery"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109134_bb0395","first-page":"694","article-title":"Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis","volume":"56","author":"Gomez-Manzano","year":"1996","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb0400","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2015.1138017","article-title":"Tight junction modulation of the blood brain barrier: CNS delivery of small molecules","volume":"4","author":"Greene","year":"2016","journal-title":"Tissue Barriers"},{"issue":"19","key":"10.1016\/j.pharmthera.2026.109134_bb0405","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/s41388-024-03000-9","article-title":"p53 modulates kinase inhibitor resistance and lineage plasticity in NF1-related MPNSTs","volume":"43","author":"Grit","year":"2024","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109134_bb0410","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.nantod.2015.06.006","article-title":"Nanoparticle uptake: The phagocyte problem","volume":"10","author":"Gustafson","year":"2015","journal-title":"Nano Today"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109134_bb0415","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"The Journal of Clinical Investigation"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb0420","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nn.4185","article-title":"The role of microglia and macrophages in glioma maintenance and progression","volume":"19","author":"Hambardzumyan","year":"2016","journal-title":"Nature Neuroscience"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109134_bb0425","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1006\/mthe.2002.0549","article-title":"Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood","volume":"5","author":"Hanawa","year":"2002","journal-title":"Molecular Therapy"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109134_bb0430","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/neuonc\/noad108","article-title":"Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma","volume":"25","author":"Hansch","year":"2023","journal-title":"Neuro-Oncology"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109134_bb0435","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nri1489","article-title":"Retroviral restriction by APOBEC proteins","volume":"4","author":"Harris","year":"2004","journal-title":"Nature Reviews. Immunology"},{"issue":"25","key":"10.1016\/j.pharmthera.2026.109134_bb0440","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2007.11.5964","article-title":"Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity","volume":"26","author":"Hegi","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109134_bb0445","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/80474","article-title":"An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy","volume":"6","author":"Heise","year":"2000","journal-title":"Nature Medicine"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109134_bb0450","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/neuonc\/nor098","article-title":"RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo","volume":"13","author":"Hendruschk","year":"2011","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2026.109134_bb0455","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1507940","article-title":"Identifying new therapeutics for focused ultrasound-enhanced drug delivery in the management of glioblastoma","volume":"15","author":"Holman","year":"2025","journal-title":"Frontiers in Oncology"},{"issue":"7237","key":"10.1016\/j.pharmthera.2026.109134_bb0460","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nature07725","article-title":"AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC","volume":"458","author":"Hornung","year":"2009","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109134_bb0465","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nri2690","article-title":"Intracellular DNA recognition","volume":"10","author":"Hornung","year":"2010","journal-title":"Nature Reviews. Immunology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb0470","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4161\/15384047.2014.986944","article-title":"Sleeping beauty transposon system for genetic etiological research and gene therapy of cancers","volume":"16","author":"Hou","year":"2015","journal-title":"Cancer Biology & Therapy"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109134_bb0475","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1006\/bbrc.1997.6459","article-title":"Intracavitary liposome-mediated p53 gene transfer into glioblastoma with endogenous wild-type p53 in vivo results in tumor suppression and long-term survival","volume":"233","author":"Hsiao","year":"1997","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109134_bb0480","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nbt.2647","article-title":"DNA targeting specificity of RNA-guided Cas9 nucleases","volume":"31","author":"Hsu","year":"2013","journal-title":"Nature Biotechnology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb0485","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1080\/10717544.2017.1373166","article-title":"Development of DNA tetrahedron-based drug delivery system","volume":"24","author":"Hu","year":"2017","journal-title":"Drug Delivery"},{"issue":"15","key":"10.1016\/j.pharmthera.2026.109134_bb0490","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00841-18","article-title":"Herpes simplex virus 1 tegument protein VP22 abrogates cGAS\/STING-mediated antiviral innate immunity","volume":"92","author":"Huang","year":"2018","journal-title":"Journal of Virology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109134_bb0495","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11060-006-9279-x","article-title":"Exogenous wt-p53 enhances the antitumor effect of HSV-TK\/GCV on C6 glioma cells","volume":"82","author":"Huang","year":"2007","journal-title":"Journal of Neuro-Oncology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109134_bb0500","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nbt1399","article-title":"CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression","volume":"26","author":"Hyde","year":"2008","journal-title":"Nature Biotechnology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb0505","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nature Reviews. Immunology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109134_bb0510","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001268","article-title":"p53 regulates cell cycle and microRNAs to promote differentiation of human embryonic stem cells","volume":"10","author":"Jain","year":"2012","journal-title":"PLoS Biology"},{"issue":"209","key":"10.1016\/j.pharmthera.2026.109134_bb0515","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006839","article-title":"Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma","volume":"5","author":"Jensen","year":"2013","journal-title":"Science Translational Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109134_bb0520","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.18632\/oncotarget.6737","article-title":"Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma","volume":"7","author":"Ji","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2026.109134_bb0525","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","article-title":"CRISPR-Cas9 structures and mechanisms","volume":"46","author":"Jiang","year":"2017","journal-title":"Annual Review of Biophysics"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109134_bb0530","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.immuni.2014.02.006","article-title":"Noncanonical NF-kappaB pathway controls the production of type I interferons in antiviral innate immunity","volume":"40","author":"Jin","year":"2014","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109134_bb0535","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1021\/bc500252a","article-title":"Optimization of liganded polyethylenimine polyethylene glycol vector for nucleic acid delivery","volume":"25","author":"Joubran","year":"2014","journal-title":"Bioconjugate Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109134_bb0540","doi-asserted-by":"crossref","DOI":"10.1021\/acsnano.2c04543","article-title":"Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine","author":"Ju","year":"2022","journal-title":"ACS Nano"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109134_bb0545","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14081925","article-title":"Targeted transposition of minicircle DNA using single-chain antibody conjugated cyclodextrin-modified poly (propylene imine) nanocarriers","volume":"14","author":"Jugel","year":"2022","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109134_bb0550","doi-asserted-by":"crossref","DOI":"10.3390\/life15101582","article-title":"Innate immune signaling in gliomas: Regulatory mechanisms and targeting potential in tumor progression","volume":"15","author":"Jung","year":"2025","journal-title":"Life"},{"key":"10.1016\/j.pharmthera.2026.109134_bb0555","doi-asserted-by":"crossref","unstructured":"Kale, J., Kutuk, O., Brito, G. C., Andrews, T. S., Leber, B., Letai, A., & Andrews, D. W. (2018). Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance. EMBO Reports, 19(9). e45235 doi:10.15252\/embr.201745235.","DOI":"10.15252\/embr.201745235"},{"key":"10.1016\/j.pharmthera.2026.109134_bb0560","article-title":"Tyrosine-modified linear PEIs for highly efficacious and biocompatible siRNA delivery in vitro and in vivo","volume":"36","author":"Karimov","year":"2021","journal-title":"Nanomedicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109134_bb0565","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2144\/05392ST01","article-title":"Inducible control of transgene expression with ecdysone receptor: Gene switches with high sensitivity, robust expression, and reduced size","volume":"39","author":"Karzenowski","year":"2005","journal-title":"Biotechniques"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109134_bb0570","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109134_bb0575","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1128\/JCM.00180-06","article-title":"Prevalence of antibodies against herpes simplex virus types 1 and 2 in children and young people in an urban region in Tanzania","volume":"44","author":"Kasubi","year":"2006","journal-title":"Journal of Clinical Microbiology"},{"key":"10.1016\/j.pharmthera.2026.109134_bb0580","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.60821","article-title":"HIV-1 Vpr antagonizes innate immune activation by targeting karyopherin-mediated NF-kappaB\/IRF3 nuclear transport","volume":"9","author":"Khan","year":"2020","journal-title":"Elife"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109134_bb0585","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s12035-011-8172-6","article-title":"p73: a multifunctional protein in neurobiology","volume":"43","author":"Killick","year":"2011","journal-title":"Molecular Neurobiology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109134_bb0590","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1021\/mp4006003","article-title":"Delivery of hypoxia and glioma dual-specific suicide gene using dexamethasone conjugated polyethylenimine for glioblastoma-specific gene therapy","volume":"11","author":"Kim","year":"2014","journal-title":"Molecular Pharmaceutics"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109134_bb0595","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1002\/ijc.32531","article-title":"A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma","volume":"145","author":"Kim","year":"2019","journal-title":"International Journal of Cancer"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109134_bb0600","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.nano.2014.09.005","article-title":"A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme","volume":"11","author":"Kim","year":"2015","journal-title":"Nanomedicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109134_bb0605","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1021\/nn5014484","article-title":"A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival","volume":"8","author":"Kim","year":"2014","journal-title":"ACS Nano"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109134_bb0610","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/(SICI)1097-0215(19960917)67:6<808::AID-IJC9>3.0.CO;2-V","article-title":"Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo","volume":"67","author":"Kock","year":"1996","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2026.109134_bb0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108762","article-title":"Recent advances in development and delivery of non-viral nucleic acid therapeutics for brain tumor therapy","volume":"266","author":"Kogel","year":"2025","journal-title":"Pharmacology & Therapeutics"},{"issue":"13","key":"10.1016\/j.pharmthera.2026.109134_bb0620","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1002\/j.1460-2075.1992.tb05614.x","article-title":"Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination","volume":"11","author":"Kotin","year":"1992","journal-title":"The EMBO Journal"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109134_bb0625","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1016\/j.ymthe.2025.08.017","article-title":"Optimized chemical structure extends silencing duration of therapeutic siRNAs in dividing cancer and immune cells","volume":"33","author":"Kremer","year":"2025","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2026.109134_bb0630","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.omtm.2019.05.014","article-title":"Prevalence of anti-adeno-associated virus immune responses in international cohorts of healthy donors","volume":"14","author":"Kruzik","year":"2019","journal-title":"Molecular Therapy - Methods & Clinical Development"},{"issue":"584","key":"10.1016\/j.pharmthera.2026.109134_bb0635","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb3945","article-title":"A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma","volume":"13","author":"Kumthekar","year":"2021","journal-title":"Science Translational Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb0640","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1038\/s41467-020-17503-y","article-title":"BRD4 prevents the accumulation of R-loops and protects against transcription-replication collision events and DNA damage","volume":"11","author":"Lam","year":"2020","journal-title":"Nature Communications"},{"issue":"13","key":"10.1016\/j.pharmthera.2026.109134_bb0645","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1200\/JCO.2003.21.13.2508","article-title":"Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: Biological and clinical results","volume":"21","author":"Lang","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb0650","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3171\/jns.1998.89.1.0125","article-title":"Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene","volume":"89","author":"Lang","year":"1998","journal-title":"Journal of Neurosurgery"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109134_bb0655","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2004.11.006","article-title":"Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome","volume":"119","author":"Lang","year":"2004","journal-title":"Cell"},{"issue":"21","key":"10.1016\/j.pharmthera.2026.109134_bb0660","doi-asserted-by":"crossref","first-page":"11169","DOI":"10.1128\/JVI.01781-15","article-title":"Knockout of cGAS and STING rescues virus infection of plasmid DNA-transfected cells","volume":"89","author":"Langereis","year":"2015","journal-title":"Journal of Virology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109134_bb0665","first-page":"374","article-title":"Interferon activation and innate immunity","volume":"2","author":"Le","year":"2000","journal-title":"Rev.Immunogenet."},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109134_bb0670","first-page":"649","article-title":"Growth inhibitory effect of triple anti-tumor gene transfer using Semliki Forest virus vector in glioblastoma cells","volume":"28","author":"Lee","year":"2006","journal-title":"International Journal of Oncology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109134_bb0675","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41588-021-00838-7","article-title":"Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing","volume":"53","author":"Leibowitz","year":"2021","journal-title":"Nature Genetics"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb0680","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1146\/annurev-pathmechdis-042524-025950","article-title":"Immunopathology of glioblastoma","volume":"21","author":"Li","year":"2026","journal-title":"Annual Review of Pathology"},{"issue":"32","key":"10.1016\/j.pharmthera.2026.109134_bb0685","doi-asserted-by":"crossref","first-page":"14188","DOI":"10.1073\/pnas.1005960107","article-title":"The ATM-p53 pathway suppresses aneuploidy-induced tumorigenesis","volume":"107","author":"Li","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb0690","article-title":"The cGAS-STING pathway in cancer: Friend or foe","volume":"17","author":"Li","year":"2026","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.pharmthera.2026.109134_bb0695","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2147\/IJN.S125286","article-title":"Hypoxia-responsive ionizable liposome delivery siRNA for glioma therapy","volume":"12","author":"Liu","year":"2017","journal-title":"International Journal of Nanomedicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb0700","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/jcb.25609","article-title":"MicroRNA control of p53","volume":"118","author":"Liu","year":"2017","journal-title":"Journal of Cellular Biochemistry"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109134_bb0705","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-020-02998-6","article-title":"PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death and Disease"},{"issue":"19","key":"10.1016\/j.pharmthera.2026.109134_bb0710","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1016\/j.biomaterials.2010.03.011","article-title":"A leptin derived 30-amino-acid peptide modified pegylated poly-L-lysine dendrigraft for brain targeted gene delivery","volume":"31","author":"Liu","year":"2010","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb0715","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-020-01253-y","article-title":"Circular RNA CDR1as disrupts the p53\/MDM2 complex to inhibit gliomagenesis","volume":"19","author":"Lou","year":"2020","journal-title":"Molecular Cancer"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109134_bb0720","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathologica"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109134_bb0725","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109134_bb0730","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ccell.2022.04.009","article-title":"Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition","volume":"40","author":"Low","year":"2022","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109134_bb0735","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1086\/314498","article-title":"Prevalence of antibodies to adenovirus serotypes 4 and 7 among unimmunized US Army trainees: Results of a retrospective nationwide seroprevalence survey","volume":"178","author":"Ludwig","year":"1998","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2026.109134_bb0740","doi-asserted-by":"crossref","unstructured":"Lukas, R. V., Kurz, S. C., Yu, J., Landolfi, J. C., Rao, G., Amidei, C., \u2026 Laurence, J. N. (2020). Survival of subjects with recurrent glioblastoma receiving intratumoral administration of controlled IL-12 with limited exposure to dexamethasone. Journal of Clinical Oncology, 38(15). Retrieved from:\/\/WOS:000560368301259.","DOI":"10.1200\/JCO.2020.38.15_suppl.2564"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb0745","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2006.04.014","article-title":"Toxicity of cationic lipids and cationic polymers in gene delivery","volume":"114","author":"Lv","year":"2006","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.pharmthera.2026.109134_bb0750","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jconrel.2020.12.050","article-title":"In situ-gelling starch nanoparticle (SNP)\/-carboxymethyl chitosan (CMCh) nanoparticle network hydrogels for the intranasal delivery of an antipsychotic peptide","volume":"330","author":"Majcher","year":"2021","journal-title":"Journal of Controlled Release"},{"issue":"24","key":"10.1016\/j.pharmthera.2026.109134_bb0755","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1182\/blood-2010-10-314518","article-title":"The genome of self-complementary adeno-associated viral vectors increases toll-like receptor 9-dependent innate immune responses in the liver","volume":"117","author":"Martino","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2026.109134_bb0760","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jconrel.2017.07.009","article-title":"Biodegradable brain-penetrating DNA nanocomplexes and their use to treat malignant brain tumors","volume":"262","author":"Mastorakos","year":"2017","journal-title":"Journal of Controlled Release"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109134_bb0765","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/cdd.2011.81","article-title":"p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53","volume":"18","author":"Melino","year":"2011","journal-title":"Cell Death and Differentiation"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb0770","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1021\/acsnano.4c05906","article-title":"pH-responsive polyethylene glycol engagers for enhanced brain delivery of PEGylated nanomedicine to treat glioblastoma","volume":"19","author":"Meng","year":"2025","journal-title":"ACS Nano"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109134_bb0775","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.ymthe.2017.03.037","article-title":"A basic ApoE-based peptide mediator to deliver proteins across the blood-brain barrier: Long-term efficacy, toxicity, and mechanism","volume":"25","author":"Meng","year":"2017","journal-title":"Molecular Therapy"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109134_bb0780","first-page":"178","article-title":"Lost in disruption: Role of proteases in glioma invasion and progression","volume":"1825","author":"Mentlein","year":"2012","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2026.109134_bb0785","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mrrev.2017.02.003","article-title":"When the guardian sleeps: Reactivation of the p53 pathway in cancer","volume":"773","author":"Merkel","year":"2017","journal-title":"Mutation Research, Reviews in Mutation Research"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109134_bb0790","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1039\/D2BM00181K","article-title":"Nanoparticle based medicines: approaches for evading and manipulating the mononuclear phagocyte system and potential for clinical translation","volume":"10","author":"Mills","year":"2022","journal-title":"Biomaterials Science"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109134_bb0795","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/cbf.3590","article-title":"Context is key: Understanding the regulation, functional control, and activities of the p53 tumour suppressor","volume":"39","author":"Moxley","year":"2021","journal-title":"Cell Biochemistry and Function"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb0800","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1021\/acs.molpharmaceut.4c00870","article-title":"Synthesis and characterization of transferrin and cell-penetrating peptide-functionalized liposomal nanoparticles to deliver plasmid ApoE2 in vitro and in vivo in mice","volume":"22","author":"Muolokwu","year":"2025","journal-title":"Molecular Pharmaceutics"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109134_bb0805","doi-asserted-by":"crossref","DOI":"10.1002\/eji.70024","article-title":"Immunological impact of oncolytic adenoviruses on cancer therapy: Clinical insights","volume":"55","author":"Nadafi","year":"2025","journal-title":"European Journal of Immunology"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109134_bb0810","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25073948","article-title":"The MDM2-p53 Axis represents a therapeutic vulnerability unique to glioma stem cells","volume":"25","author":"Nakagawa-Saito","year":"2024","journal-title":"International Journal of Molecular Sciences"},{"issue":"21","key":"10.1016\/j.pharmthera.2026.109134_bb0815","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"The New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109134_bb0820","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103479","article-title":"The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory","volume":"24","author":"Ndeupen","year":"2021","journal-title":"Iscience"},{"issue":"7177","key":"10.1016\/j.pharmthera.2026.109134_bb0825","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nature06553","article-title":"Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu","volume":"451","author":"Neil","year":"2008","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109134_bb0830","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14102213","article-title":"Development of WRAP5 peptide complexes for targeted drug\/gene co-delivery toward glioblastoma therapy","volume":"14","author":"Neves","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb0835","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41587-025-02945-w","article-title":"Targeted delivery of genome editors in vivo","volume":"44","author":"Ngo","year":"2026","journal-title":"Nature Biotechnology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109134_bb0840","first-page":"351","article-title":"Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of the Gambia, South Africa, and the United States","volume":"11","author":"Nwanegbo","year":"2004","journal-title":"Clinical and Diagnostic Laboratory Immunology"},{"issue":"399","key":"10.1016\/j.pharmthera.2026.109134_bb0860","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O'Rourke","year":"2017","journal-title":"Science Translational Medicine"},{"issue":"24","key":"10.1016\/j.pharmthera.2026.109134_bb0845","doi-asserted-by":"crossref","first-page":"21843","DOI":"10.1074\/jbc.M109745200","article-title":"Akt enhances Mdm2-mediated ubiquitination and degradation of p53","volume":"277","author":"Ogawara","year":"2002","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109134_bb0850","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.745016","article-title":"Exploration of pattern recognition receptor agonists as candidate adjuvants","volume":"11","author":"Ong","year":"2021","journal-title":"Frontiers in Cellular and Infection Microbiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb0855","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-26030-3","article-title":"Effects of pre-existing anti-adenovirus antibodies on transgene expression levels and therapeutic efficacies of arming oncolytic adenovirus","volume":"12","author":"Ono","year":"2022","journal-title":"Scientific Reports"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109134_bb0865","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11060-026-05431-8","article-title":"Magnetic resonance imaging features differentiate histologic and molecular subtypes of glioblastoma IDH-Wild type CNS WHO grade 4","volume":"176","author":"Patel","year":"2026","journal-title":"Journal of Neuro-Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109134_bb0870","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.100820","article-title":"Oncogenic gain of function in glioblastoma is linked to mutant p53 amyloid oligomers","volume":"23","author":"Pedrote","year":"2020","journal-title":"Iscience"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109134_bb0875","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1089\/hum.2005.16.1016","article-title":"Current status of gendicine in China: Recombinant human ad-p53 agent for treatment of cancers","volume":"16","author":"Peng","year":"2005","journal-title":"Human Gene Therapy"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109134_bb0880","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/humu.20495","article-title":"Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database","volume":"28","author":"Petitjean","year":"2007","journal-title":"Human Mutation"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109134_bb0885","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.devcel.2008.04.014","article-title":"Polo on the rise-from mitotic entry to cytokinesis with Plk1","volume":"14","author":"Petronczki","year":"2008","journal-title":"Developmental Cell"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109134_bb0890","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/mt.2016.135","article-title":"Safety and efficacy in advanced solid tumors of a targeted nanocomplex carrying the p53 gene used in combination with docetaxel: a phase 1b study","volume":"24","author":"Pirollo","year":"2016","journal-title":"Molecular Therapy"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109134_bb0895","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.3390\/cells12182307","article-title":"Astrocytes are a key target for neurotropic viral infection","volume":"12","author":"Potokar","year":"2023","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109134_bb0900","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/0008-5472.CAN-12-4561","article-title":"Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology","volume":"73","author":"Prabhakar","year":"2013","journal-title":"Cancer Research"},{"issue":"17","key":"10.1016\/j.pharmthera.2026.109134_bb0905","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1089\/104303400750038499","article-title":"A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme","volume":"11","author":"Rainov","year":"2000","journal-title":"Human Gene Therapy"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109134_bb0910","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/nm1297-1354","article-title":"Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells","volume":"3","author":"Ram","year":"1997","journal-title":"Nature Medicine"},{"issue":"1-2","key":"10.1016\/j.pharmthera.2026.109134_bb0915","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Molecular Genetics and Metabolism"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109134_bb0920","first-page":"2736","article-title":"Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations","volume":"53","author":"Reifenberger","year":"1993","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb0925","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s40478-022-01420-w","article-title":"Chromosomal instability in adult-type diffuse gliomas","volume":"10","author":"Richardson","year":"2022","journal-title":"Acta Neuropathologica Communications"},{"issue":"24","key":"10.1016\/j.pharmthera.2026.109134_bb0930","first-page":"6091","article-title":"Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification","volume":"59","author":"Riemenschneider","year":"1999","journal-title":"Cancer Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109134_bb0935","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood-2004-06-2501","article-title":"Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer","volume":"105","author":"Rivera","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109134_bb0940","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1177\/1947601911408889","article-title":"Mutations in the p53 tumor suppressor gene: Important milestones at the various steps of tumorigenesis","volume":"2","author":"Rivlin","year":"2011","journal-title":"Genes & Cancer"},{"issue":"13","key":"10.1016\/j.pharmthera.2026.109134_bb0945","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23137207","article-title":"Glioblastoma treatment: state-of-the-art and future perspectives","volume":"23","author":"Rodriguez-Camacho","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109134_bb0950","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41416-020-01136-5","article-title":"Tumour treating fields therapy for glioblastoma: current advances and future directions","volume":"124","author":"Rominiyi","year":"2021","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2026.109134_bb0955","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2026.112692","article-title":"MRI features of molecular glioblastoma: Morphological and advanced imaging insights","volume":"196","author":"Roques","year":"2026","journal-title":"European Journal of Radiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb0960","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s12943-025-02495-4","article-title":"Context-dependent impact of type I interferon signaling in cancer","volume":"24","author":"Ruiz-Iglesias","year":"2025","journal-title":"Molecular Cancer"},{"key":"10.1016\/j.pharmthera.2026.109134_bb0965","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.omtm.2020.10.002","article-title":"Envelope-specific adaptive immunity following transplantation of hematopoietic stem cells modified with VSV-G lentivirus","volume":"19","author":"Rust","year":"2020","journal-title":"Molecular Therapy - Methods & Clinical Development"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109134_bb0970","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1021\/acsbiomaterials.3c00263","article-title":"Angiopep-2 grafted PAMAM dendrimers for the targeted delivery of temozolomide: In vitro and in vivo effects of PEGylation in the management of glioblastoma multiforme","volume":"9","author":"Sahoo","year":"2023","journal-title":"ACS Biomaterials Science & Engineering"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109134_bb0975","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22105084","article-title":"Contemporary transposon tools: A review and guide through mechanisms and applications of sleeping beauty, piggyBac and Tol2 for genome engineering","volume":"22","author":"Sandoval-Villegas","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2026.109134_bb0980","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123785","article-title":"Restoration of p53 mRNA combined with BRD4 silencing by brain targeted nanocapsules achieves effective combinatorial treatment of glioblastoma","volume":"327","author":"Sang","year":"2026","journal-title":"Biomaterials"},{"issue":"43","key":"10.1016\/j.pharmthera.2026.109134_bb0985","doi-asserted-by":"crossref","first-page":"18511","DOI":"10.1073\/pnas.1006124107","article-title":"p53-dependent regulation of autophagy protein LC3 supports cancer cell survival under prolonged starvation","volume":"107","author":"Scherz-Shouval","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109134_bb0990","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ng.3673","article-title":"An inducible long noncoding RNA amplifies DNA damage signaling","volume":"48","author":"Schmitt","year":"2016","journal-title":"Nature Genetics"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109134_bb0995","first-page":"2742","article-title":"APOBEC3B is expressed in human glioma, and influences cell proliferation and temozolomide resistance","volume":"40","author":"Schmitt","year":"2018","journal-title":"Oncology Reports"},{"issue":"5 Pt 1","key":"10.1016\/j.pharmthera.2026.109134_bb1000","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1006\/mthe.2001.0330","article-title":"Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors","volume":"3","author":"Schnell","year":"2001","journal-title":"Molecular Therapy"},{"issue":"22","key":"10.1016\/j.pharmthera.2026.109134_bb1005","doi-asserted-by":"crossref","first-page":"10097","DOI":"10.1128\/MCB.25.22.10097-10110.2005","article-title":"Tumor-derived p53 mutants induce NF-kappaB2 gene expression","volume":"25","author":"Scian","year":"2005","journal-title":"Molecular and Cellular Biology"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109134_bb1010","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1089\/10430349950016979","article-title":"A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group","volume":"10","author":"Shand","year":"1999","journal-title":"Human Gene Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb1015","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-022-03729-5","article-title":"Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products","volume":"20","author":"Shao","year":"2022","journal-title":"Journal of Translational Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb1020","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/v2010244","article-title":"Virus infection recognition and early innate responses to non-enveloped viral vectors","volume":"2","author":"Shayakhmetov","year":"2010","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109134_bb1025","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune responses to viral gene therapy vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.pharmthera.2026.109134_bb1030","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2014.06.006","article-title":"Transferrin-bearing polypropylenimine dendrimer for targeted gene delivery to the brain","volume":"188","author":"Somani","year":"2014","journal-title":"Journal of Controlled Release"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109134_bb1035","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.colsurfb.2008.07.004","article-title":"Biodistribution of colloidal gold nanoparticles after intravenous administration: Effect of particle size","volume":"66","author":"Sonavane","year":"2008","journal-title":"Colloids and Surfaces. B, Biointerfaces"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109134_bb1040","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/ncb1571","article-title":"P53 gain-of-function cancer mutants induce genetic instability by inactivating ATM","volume":"9","author":"Song","year":"2007","journal-title":"Nature Cell Biology"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109134_bb1045","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.celrep.2017.05.055","article-title":"p53 prohibits propagation of chromosome segregation errors that produce structural aneuploidies","volume":"19","author":"Soto","year":"2017","journal-title":"Cell Reports"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109134_bb1050","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","article-title":"Gene regulation by long non-coding RNAs and its biological functions","volume":"22","author":"Statello","year":"2021","journal-title":"Nature Reviews. Molecular Cell Biology"},{"issue":"19","key":"10.1016\/j.pharmthera.2026.109134_bb1055","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1101\/gad.1924710","article-title":"Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor","volume":"24","author":"Stegh","year":"2010","journal-title":"Genes & Development"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb1060","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1101\/gad.1480007","article-title":"Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma","volume":"21","author":"Stegh","year":"2007","journal-title":"Genes & Development"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109134_bb1065","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nsmb.1744","article-title":"APOBEC3 proteins mediate the clearance of foreign DNA from human cells","volume":"17","author":"Stenglein","year":"2010","journal-title":"Nature Structural & Molecular Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb1070","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41434-023-00405-1","article-title":"Adeno-associated virus vectors and neurotoxicity-lessons from preclinical and human studies","volume":"32","author":"Stone","year":"2025","journal-title":"Gene Therapy"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109134_bb1075","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"The Lancet Oncology"},{"issue":"23","key":"10.1016\/j.pharmthera.2026.109134_bb1080","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109134_bb1085","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1073\/pnas.1202465109","article-title":"MicroRNAs\/TP53 feedback circuitry in glioblastoma multiforme","volume":"109","author":"Suh","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109134_bb1090","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1006\/bbrc.2001.5707","article-title":"RNAi in mouse oocytes and preimplantation embryos: Effectiveness of hairpin dsRNA","volume":"287","author":"Svoboda","year":"2001","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109134_bb1095","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1349-7006.2006.00208.x","article-title":"Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy","volume":"97","author":"Szatmari","year":"2006","journal-title":"Cancer Science"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109134_bb1100","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","article-title":"IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines","volume":"23","author":"Tahtinen","year":"2022","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2026.109134_bb1105","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.omto.2022.01.013","article-title":"Synthetic mRNA-based gene therapy for glioblastoma: TRAIL-mRNA synergistically enhances PTEN-mRNA-based therapy","volume":"24","author":"Tang","year":"2022","journal-title":"Molecular Therapy - Oncolytics"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb1110","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1038\/s41467-022-30311-w","article-title":"Synthetic lethality between TP53 and ENDOD1","volume":"13","author":"Tang","year":"2022","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2026.109134_bb1115","doi-asserted-by":"crossref","unstructured":"Temme, A., Rieger, M., Reber, F., Lindemann, D., Weigle, B., estelkoetter-Bachert, P., \u2026 Rieber, E. P. (2003). Localization, dynamics, and function of survivin revealed by expression of functional survivinDsRed fusion proteins in the living cell. Mol.Biol.Cell, 14(1), 78\u201392. (Retrieved from PM:12529428).","DOI":"10.1091\/mbc.e02-04-0182"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb1120","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1515\/iss-2020-0034","article-title":"Prospects of immune checkpoint blockade and vaccine-based immunotherapy for glioblastoma","volume":"6","author":"Tietze","year":"2021","journal-title":"Innovative Surgical Sciences"},{"issue":"27","key":"10.1016\/j.pharmthera.2026.109134_bb1125","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201700072","article-title":"A poly(Propyleneimine) dendrimer-based polyplex-system for single-chain antibody-mediated targeted delivery and cellular uptake of SiRNA","volume":"13","author":"Tietze","year":"2017","journal-title":"Small"},{"key":"10.1016\/j.pharmthera.2026.109134_bb1130","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1355242","article-title":"Insights into the glioblastoma tumor microenvironment: Current and emerging therapeutic approaches","volume":"15","author":"Tripathy","year":"2024","journal-title":"Frontiers in Pharmacology"},{"issue":"21","key":"10.1016\/j.pharmthera.2026.109134_bb1135","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1016\/j.cell.2023.08.041","article-title":"Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells","volume":"186","author":"Tsuchida","year":"2023","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109134_bb1140","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S1470-2045(23)00347-9","article-title":"Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: A phase 1, first-in- human trial","volume":"24","author":"Umemura","year":"2023","journal-title":"Lancet Oncology"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109134_bb1145","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/ni.1932","article-title":"IFI16 is an innate immune sensor for intracellular DNA","volume":"11","author":"Unterholzner","year":"2010","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2026.109134_bb1150","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108832","article-title":"Design and evaluation of thermo-responsive nasal gelling system dispersed with piribedil loaded lecithin-chitosan hybrid nanoparticles for improved brain availability","volume":"201","author":"Uppuluri","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2026.109134_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2022.213125","article-title":"Transport of nanomedicines across the blood-brain barrier: Challenges and opportunities for imaging and therapy","volume":"141","author":"van den Broek","year":"2022","journal-title":"Biomaterials Advances"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109134_bb1155","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.4161\/cc.8.18.9539","article-title":"DNA damage-induced cell death is enhanced by progression through mitosis","volume":"8","author":"Varmark","year":"2009","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb1160","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.biocel.2004.06.010","article-title":"Microglia: Phagocyte and glia cell","volume":"37","author":"Vilhardt","year":"2005","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"issue":"52","key":"10.1016\/j.pharmthera.2026.109134_bb1165","first-page":"E8433","article-title":"Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5","volume":"113","author":"Vogiatzi","year":"2016","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb1170","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s13059-025-03667-7","article-title":"A base editing platform for the correction of cancer driver mutations unmasks conserved p53 transcription programs","volume":"26","author":"Wang","year":"2025","journal-title":"Genome Biology"},{"key":"10.1016\/j.pharmthera.2026.109134_bb1175","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bioactmat.2023.10.025","article-title":"DNA tetrahedral nanostructures for the biomedical application and spatial orientation of biomolecules","volume":"33","author":"Wang","year":"2024","journal-title":"Bioactive Materials"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb1180","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41423-021-00802-9","article-title":"HIV-1 Vif suppresses antiviral immunity by targeting STING","volume":"19","author":"Wang","year":"2022","journal-title":"Cellular & Molecular Immunology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109134_bb1185","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1172\/JCI44504","article-title":"Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation","volume":"121","author":"Wang","year":"2011","journal-title":"Journal of Clinical Investigation"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109134_bb1190","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s41418-022-00962-9","article-title":"Should mutant TP53 be targeted for cancer therapy?","volume":"29","author":"Wang","year":"2022","journal-title":"Cell Death and Differentiation"},{"key":"10.1016\/j.pharmthera.2026.109134_bb1195","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2014.66","article-title":"Re-examination of regulatory opinions in Europe: Possible contribution for the approval of the first gene therapy product Glybera","volume":"2","author":"Watanabe","year":"2015","journal-title":"Molecular Therapy - Methods & Clinical Development"},{"key":"10.1016\/j.pharmthera.2026.109134_bb1200","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1038\/ncomms5196","article-title":"Disruption of astrocyte-vascular coupling and the blood-brain barrier by invading glioma cells","volume":"5","author":"Watkins","year":"2014","journal-title":"Nature Communications"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109134_bb1205","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/mt.2015.138","article-title":"mRNA: Fulfilling the promise of gene therapy","volume":"23","author":"Weissman","year":"2015","journal-title":"Molecular Therapy"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109134_bb1210","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1093\/neuonc\/noaf079","article-title":"A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma","volume":"27","author":"Wen","year":"2025","journal-title":"Neuro-Oncology"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109134_bb1215","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/neuonc\/now002","article-title":"Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma","volume":"18","author":"Wheeler","year":"2016","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.pharmthera.2026.109134_bb1220","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1476-4598-13-107","article-title":"Survivin safeguards chromosome numbers and protects from aneuploidy independently from p53","volume":"13","author":"Wiedemuth","year":"2014","journal-title":"Mol.Cancer"},{"issue":"13","key":"10.1016\/j.pharmthera.2026.109134_bb1225","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1038\/sj.onc.1207396","article-title":"Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes","volume":"23","author":"Willis","year":"2004","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109134_bb1230","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1158\/1078-0432.CCR-19-2549","article-title":"EGFR amplification induces increased DNA damage response and renders selective sensitivity to Talazoparib (PARP inhibitor) in glioblastoma","volume":"26","author":"Wu","year":"2020","journal-title":"Clinical Cancer Research"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109134_bb1235","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109797","article-title":"Bromodomain protein BRD4 directs mitotic cell division of mouse fibroblasts by inhibiting DNA damage","volume":"27","author":"Wu","year":"2024","journal-title":"Iscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb1240","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41419-022-04512-6","article-title":"NEK2 enhances malignancies of glioblastoma via NIK\/NF-kappaB pathway","volume":"13","author":"Xiang","year":"2022","journal-title":"Cell Death & Disease"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109134_bb1245","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.celrep.2017.07.055","article-title":"The tumor suppressor p53 limits ferroptosis by blocking DPP4 activity","volume":"20","author":"Xie","year":"2017","journal-title":"Cell Reports"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109134_bb1250","first-page":"337","article-title":"Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes","volume":"1","author":"Xu","year":"2002","journal-title":"Molecular Cancer Therapeutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb1255","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s13045-021-01191-2","article-title":"Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma","volume":"14","author":"Xun","year":"2021","journal-title":"Journal of Hematology & Oncology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109134_bb1260","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1039\/C9TB02266J","article-title":"Mitochondria-targeted tetrahedral DNA nanostructures for doxorubicin delivery and enhancement of apoptosis","volume":"8","author":"Yan","year":"2020","journal-title":"Journal of Materials Chemistry B"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109134_bb1265","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.celrep.2015.07.016","article-title":"A positive feedback loop between Akt and mTORC2 via SIN1 phosphorylation","volume":"12","author":"Yang","year":"2015","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2026.109134_bb1270","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2147\/IJN.S286221","article-title":"Gene therapy for drug-resistant glioblastoma via lipid-polymer hybrid nanoparticles combined with focused ultrasound","volume":"16","author":"Yang","year":"2021","journal-title":"International Journal of Nanomedicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb1275","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1517\/17425247.1.1.115","article-title":"Reducing the immunostimulatory activity of CpG-containing plasmid DNA vectors for non-viral gene therapy","volume":"1","author":"Yew","year":"2004","journal-title":"Expert Opinion on Drug Delivery"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109134_bb1280","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1006\/mthe.2002.0598","article-title":"CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo","volume":"5","author":"Yew","year":"2002","journal-title":"Molecular Therapy"},{"issue":"0","key":"10.1016\/j.pharmthera.2026.109134_bb1285","first-page":"41","article-title":"Extracellular control of chromosomal instability and maintenance of intra-tumoral heterogeneity","volume":"4","author":"Yi-Hong","year":"2018","journal-title":"Journal of Cancer Metastasis and Treatment"},{"issue":"50","key":"10.1016\/j.pharmthera.2026.109134_bb1290","first-page":"E3503","article-title":"Merck Ad5\/HIV induces broad innate immune activation that predicts CD8 T-cell responses but is attenuated by preexisting Ad5 immunity","volume":"109","author":"Zak","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2026.109134_bb1295","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.biomaterials.2015.11.066","article-title":"Development of next generation adeno-associated viral vectors capable of selective tropism and efficient gene delivery","volume":"80","author":"Zhang","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmthera.2026.109134_bb1300","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2147\/DDDT.S288859","article-title":"The risks of miRNA therapeutics: In a drug target perspective","volume":"15","author":"Zhang","year":"2021","journal-title":"Drug Design, Development and Therapy"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109134_bb1305","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1038\/s41596-020-0355-z","article-title":"Design, fabrication and applications of tetrahedral DNA nanostructure-based multifunctional complexes in drug delivery and biomedical treatment","volume":"15","author":"Zhang","year":"2020","journal-title":"Nature Protocols"},{"key":"10.1016\/j.pharmthera.2026.109134_bb1310","article-title":"Reactivating P53 to treat osteosarcoma: A tetrahedral framework nucleic acids-based approach","volume":"304","author":"Zhang","year":"2025","journal-title":"International Journal of Biological Macromolecules"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109134_bb1315","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1089\/hum.2017.218","article-title":"The first approved gene therapy product for cancer ad-p53 (Gendicine): 12 years in the clinic","volume":"29","author":"Zhang","year":"2018","journal-title":"Human Gene Therapy"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109134_bb1320","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1080\/1061186X.2023.2216405","article-title":"Angiopep-2 modified dual drug-loaded liposomes with brain targeting functionality mitigate Alzheimer's disease-related symptoms in APP\/PS-1 mice","volume":"31","author":"Zhang","year":"2023","journal-title":"Journal of Drug Targeting"},{"issue":"5 Pt 1","key":"10.1016\/j.pharmthera.2026.109134_bb1325","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1006\/mthe.2001.0329","article-title":"Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages","volume":"3","author":"Zhang","year":"2001","journal-title":"Molecular Therapy"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109134_bb1330","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10090297","article-title":"The p53 pathway in glioblastoma","volume":"10","author":"Zhang","year":"2018","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109134_bb1335","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1158\/1078-0432.CCR-03-0740","article-title":"Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer","volume":"10","author":"Zhang","year":"2004","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb1340","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1006\/mthe.2002.0633","article-title":"Antisense gene therapy of brain cancer with an artificial virus gene delivery system","volume":"6","author":"Zhang","year":"2002","journal-title":"Molecular Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109134_bb1345","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41467-023-44239-2","article-title":"Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response","volume":"15","author":"Zhao","year":"2024","journal-title":"Nature Communications"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109134_bb1350","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.200148","article-title":"Exploiting aneuploidy-imposed stresses and coping mechanisms to battle cancer","volume":"10","author":"Zhou","year":"2020","journal-title":"Open Biology"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109134_bb1355","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1128\/JVI.02192-06","article-title":"Innate immune response to adenoviral vectors is mediated by both toll-like receptor-dependent and -independent pathways","volume":"81","author":"Zhu","year":"2007","journal-title":"Journal of Virology"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109134_bb1360","first-page":"709","article-title":"Treatment of recurrent malignant gliomas by surgery combined with recombinant adenovirus-p53 injection","volume":"32","author":"Zhu","year":"2010","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"16","key":"10.1016\/j.pharmthera.2026.109134_bb1365","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm8011","article-title":"Blood-brain barrier-penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy","volume":"8","author":"Zou","year":"2022","journal-title":"Science Advances"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826001610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826001610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:58:09Z","timestamp":1794412689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725826001610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":273,"alternative-id":["S0163725826001610"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109134","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nucleic acid therapeutics for reinvigorating p53 function in glioblastoma: concepts, limitations and recent advances","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109134","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109134"}}